General anesthesia drugs are administered to a patient to bring state of reversible unconsciousness and unresponsiveness before and during surgery. General anesthesia drugs are administered intravenously and by inhalation of anesthetic gases using masks. Sometimes based on the condition, both the routes are used simultaneously to anesthetize the patient. The patient administered with these drugs lose consciousness and does not feel pain during and after surgery and wakes up with some short-term amnesia (short-term loss of memory). General anesthesia drugs are intended to bring about analgesia or pain relief, amnesia, reversible unconsciousness, motionlessness, and inhibition of autonomic nervous system such as increased blood pressure, heart rate, and sweating, and to perform easier and safer surgery. 

Currently, there is a lack of standardization for technique in general anesthesia management. Anesthesiologists prefer to use one or a combination of drugs depending upon the physiological state of the patient and preference and experience of the surgeon or physician. General anesthesia drugs are used in various surgeries and the market for these drugs is expected to be driven by the increasing number of surgeries such as cardiac, orthopedic, general surgeries, and others across the globe. Further, the technological advancements in drug delivery devices, development of specific targeted drugs and patient monitoring devices for monitoring physiological parameters of patients during and after anesthesia, and minimized side effects of anesthetic drugs are drivers which are likely to boost the market growth during the forecast period. However, lack of health care facilities in underdeveloped countries and in remote areas and few  anesthetic doctors and certified anesthetic nurses per capita of population are anticipated to restrain the growth of the general anesthesia drugs market. Moreover, high cost of procedures and branded drugs is expected to limit the growth of this market during the forecast period.

The global general anesthesia drugs market can be segmented on the basis of drug molecule, route of administration, and region. Based on the drug molecule, the market is segmented into isoflurane, desflurane, sevoflurane, ketamine, thiopental, opioids, propofol, and others. Based on the route of administration, the market is segmented into intravenous anesthesia drugs and inhaled anesthesia drugs. Among the drugs used for general anesthesia, isoflurane, desflurane, and sevoflurane are administered by inhalation, while the rest are administered intravenously. Intravenous anesthetic drugs are administered through the veins while inhaled anesthetic drugs are administered through anesthesia masks and endotracheal tubes using ventilators. 

Geographically, the global general anesthesia drugs market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe dominated the global market and are expected to hold a significant market share during the forecast period owing to high health care expenditure and increase number of surgeries being performed. Asia Pacific is expected to witness a strong growth in the next few years with the increasing number of hospitals and health care reforms to improve access to health care facilities to general public.

Key players operating in the general anesthesia drugs market are AbbVie Inc., B. Braun Melsungen AG, Fresenius SE & Co. KGaA, Hospira Inc. (part of Pfizer Inc.), Baxter International Inc., AstraZeneca PLC, Par Pharmaceutical Companies, Inc., Mylan N.V., Abbott Laboratories, and Eisai Co., Ltd. Among these companies, Baxter International Inc., Fresenius SE & C. KGaA, and Abbott Laboratories held a significant share of the market with wide distribution network across the globe and proven track record during the last few decades.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


General Anesthsia Drugs Market

Pre Book